Jardiance 10 mg (Empagliflozin) – Product Overview

Jardiance is a prescription medication that contains empagliflozin, a selective inhibitor of the sodium‑glucose co‑transporter‑2 (SGLT2) protein. It is indicated for the treatment of Type 2 diabetes mellitus in adults when diet and exercise alone do not achieve adequate glycemic control. The drug is manufactured by Boehringer Ingelheim India Pvt. Ltd., a globally recognized pharmaceutical company with a reputation for rigorous quality standards. Each strip of Jardiance contains ten film‑coated tablets, and the product is marketed in pack sizes of 30, 60, or 90 tablets to accommodate varying treatment durations. The 10 mg strength represents the most commonly prescribed dose for initiating therapy in patients with a baseline estimated glomerular filtration rate (eGFR) above 45 mL/min/1.73 m².

What is Jardiance 10 mg?

Jardiance 10 mg is the standard starting dose of empagliflozin used to lower blood glucose in individuals diagnosed with Type 2 diabetes. The active ingredient works by blocking the SGLT2 transporter in the proximal renal tubule, which reduces the reabsorption of filtered glucose. As a result, excess glucose is excreted in the urine, leading to a measurable decline in circulating glucose levels. The 10 mg tablet delivers precisely 10 milligrams of empagliflozin, ensuring consistent pharmacokinetic exposure across patients. This dose is generally well tolerated and provides a favorable balance between efficacy and safety for most patients initiating treatment.

Uses and Benefits

The primary therapeutic use of Jardiance is to improve glycemic control in adults with Type 2 diabetes mellitus. Clinical trials have demonstrated that empagliflozin, at a dose of 10 mg daily, can reduce HbA1c by approximately 0.8 % to 1.0 % when added to standard antidiabetic regimens. Beyond glucose lowering, the medication confers additional cardiometabolic advantages. Studies have shown a reduction in hospitalizations for heart failure, modest improvements in systolic blood pressure, and a small but consistent loss of body weight. These effects make Jardiance an attractive option for patients who have concomitant cardiovascular risk factors such as hypertension or dyslipidemia. Furthermore, the once‑daily oral administration simplifies the treatment regimen and enhances adherence.

How It Works

Empagliflozin exerts its pharmacological effect by selectively inhibiting the SGLT2 protein located in the early portion of the renal tubule. Under normal physiological conditions, SGLT2 reabsorbs approximately 90 % of filtered glucose back into the bloodstream. By blocking this transporter, Jardiance prevents glucose reabsorption, causing an increase in urinary glucose excretion. This mechanism leads to a caloric loss of roughly 300–400 kilocalories per day, which contributes to modest weight reduction. Additionally, the osmotic diuresis induced by glucose loss can lower blood pressure and improve fluid balance. The drug’s half‑life is approximately 12 hours, supporting once‑daily dosing.

Dosage Guidelines

The recommended initial dosage of Jardiance is one 10 mg tablet taken orally once daily, irrespective of meals. If glycemic control remains suboptimal and renal function is stable (eGFR ≥ 45 mL/min/1.73 m²), the prescribing clinician may consider escalation to a 25 mg dose, which has been shown to provide greater reductions in HbA1c. Patients should be instructed to swallow the tablet whole with a full glass of water to ensure consistent absorption. It is advisable to take the medication at the same time each day to maintain steady plasma concentrations. In the event of a missed dose, the patient should take it as soon as remembered unless it is nearly time for the next scheduled dose; doubling the dose is not recommended.

Side Effects

Like all pharmaceutical agents, Jardiance can be associated with adverse effects. The most frequently reported side effects include genital mycotic infections, urinary tract infections, and an increased frequency of urination. Most of these events are mild to moderate and resolve with continued therapy or appropriate management. More serious, though less common, complications may include volume depletion, hypotension, and diabetic ketoacidosis, particularly in patients with impaired renal function or those who are concurrently using insulin or sulfonylureas. Patients should be vigilant for symptoms such as dizziness, light‑headedness, or persistent nausea, and should contact a healthcare professional promptly if such signs appear.

Warnings and Precautions

Jardiance is contraindicated in individuals with type 1 diabetes mellitus, patients who have experienced hypersensitivity reactions to empagliflozin, and those with severe renal impairment (eGFR < 30 mL/min/1.73 m²). Prior to initiation, clinicians should assess renal function, hepatic status, and cardiovascular history. Caution is advised in patients who are elderly, have low body weight, or are taking diuretic medications, as these factors can increase the risk of dehydration. Alcohol consumption should be moderated, and patients should be instructed to maintain adequate fluid intake, especially in hot weather or during periods of illness that may lead to reduced fluid intake. Pregnant or breastfeeding women should not use Jardiance without a thorough risk‑benefit evaluation by a qualified physician.

Frequently Asked Questions

Q1: Can Jardiance be used for weight loss?
A: Weight reduction is observed in many users as a secondary effect, but the medication is not prescribed solely for that purpose. Any loss of body weight should be viewed as an added benefit alongside its primary role in glycemic control.

Q2: How long does it take to see glucose‑lowering effects?
A: Most patients notice a decrease in fasting blood glucose within the first two weeks of consistent use. Full therapeutic effect on HbA1c typically becomes evident after 12 weeks of continuous treatment.

Q3: Is Jardiance safe for patients with heart disease?
A: Clinical investigations have demonstrated cardiovascular benefits, including a lower incidence of hospitalization for heart failure, in patients with Type 2 diabetes who also have established heart disease. Nevertheless, a physician must evaluate each patient’s cardiac condition before initiating therapy.

Q4: What should I do if I miss a dose?
A: Take the missed tablet as soon as you remember, provided it is not close to the time of the next scheduled dose. If it is, skip the missed dose and resume the regular dosing schedule; do not take two doses at once.

Q5: Can I purchase Jardiance without a prescription?
A: No. Jardiance is a prescription‑only medication. A licensed healthcare provider must issue a valid prescription for legal acquisition.

For authoritative scientific information, consult the National Library of Medicine, the U.S. Food and Drug Administration, and the Mayo Clinic.

Related Products

• Dabigatran Etexilate 75mg (Generic)
• Glucagen Injection (Glucagon)
• Empagliflozin 25 mg Tablet
• Pradaxa (Dabigatran Etexilate)
• Pradaxa 75mg (Dabigatran Etexilate)
• Pradaxa 110mg (Dabigatran Etexilate)
• Pradaxa 150mg (Dabigatran Etexilate)
• Xovoltib (Afatinib Dimaleate)
• Xovoltib 20 mg (Afatinib Dimaleate)
• Xovoltib 30 mg (Afatinib Dimaleate)
• Xovoltib 40 mg (Afatinib Dimaleate)
• Xovoltib 50 mg (Afatinib Dimaleate)